:Ki67

Ângela Albuquerque-Castro1,2, Catarina Macedo-Silva1, Rúben Oliveira-Sousa1,2

  • 1Cancer Biology & Epigenetics Group, Research Center of IPO Porto (CI-IPOP)/ CI-IPOP@ RISE (Health Research Network), Portuguese Oncology Institute of Porto (IPO-Porto)/Porto Comprehensive Cancer Center Raquel Seruca (Porto.CCC), R. Dr. António Bernardino de Almeida, 4200-072, Porto, Portugal.

Biomarker research
|August 1, 2024
PubMed
概括

使用Ki67指数和临床病理特征开发新的风险计算器有助于精确选择前列腺癌 (PCa) 患者进行积极监测,改善患者的治疗结果和预后.